The FDA has granted Biotronik approval for its implantable cardioverter defibrillator that uses advanced sensors and the company's LinoxsmartS DX lead to allow doctors to monitor and detect atrial arrhythmias with just one lead. The device, called Lumax 740 DX System, is targeted for implantation in the U.S. starting late this month or early next month.
Biotronik wins FDA nod for single-lead, atrial-sensing ICD
SmartBrief Job Listings for Health Care
|Junior to Mid-Level FDA Associate||
|Global Counsel - Advertising and Promotions||
|Associate Director, Compliance & Ethics, US Operations Ops II||
|Senior Associate, Health Economics - Heart Valve Therapy||
|Health Economics & Reimbursement Manager - Transcatheter Heart Valve||